Company to Highlight the Role of Precision Diagnostics in Transforming Rare and Undiagnosed Disease CareHOUSTON, Aug. 25, ...

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Oncologists and scientists warn that extensive cuts to mRNA funding will have devastating impacts on cancer vaccine ...

Certain types of biochemical processes can impair the immune system's ability to recognize and kill cancer cells. Purdue ...

After a person survives a heart attack, the heart has a brief window of time in which it can heal if the right circumstances ...

Tuberculosis (TB) is the world's deadliest infectious disease—and one of the hardest to cure. Standard treatment requires a ...

A close associate of the HHS secretary claims the U.S. government will soon pull COVID-19 mRNA jabs from the market.

While healthtech provides the digital infra to widen reach, the true potential of healthcare and its quality can only be ...

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...